New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free

Bronchogen

Also known as: Ala-Glu-Asp-Leu, Khavinson lung peptide, Bronchial bioregulator

Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.

Half-Life

Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting

Route

SubQ, Oral

Category

Anti-Aging & Longevity

Studies

5 references

Key Benefits

  • Tissue-specific support for bronchial and lung health
  • Promotes normalization of bronchial epithelial cell function
  • Potential benefits in chronic bronchitis and COPD support
  • Anti-aging effects on pulmonary tissue
  • May reduce frequency of respiratory infections
  • Supports lung function preservation with aging
  • Compatible with other Khavinson bioregulator peptides

Mechanism of Action

As a short peptide bioregulator, Bronchogen penetrates cell nuclei and interacts with gene promoter sequences in bronchial epithelial cells, acting as a gene expression modulator. It normalizes protein synthesis in bronchial tissue, promotes cellular regeneration, and reduces degenerative changes associated with aging or chronic lung disease. The tetrapeptide sequence Ala-Glu-Asp-Leu is homologous to bronchial tissue proteins, conferring tissue specificity.

Dosing Protocols

Standard Khavinson Protocol

Dose
10 mg per day
Frequency
Daily for 10–30 days
Timing
Subcutaneous injection or oral (enteric-coated)
Cycle
10–30 day course, repeated 2–4x per year

Standard Khavinson Institute protocol. Often combined with other organ-specific bioregulators. Research use only.

Calculate your draw volume

Enter your vial size and BAC water to get exact injection volumes

Calculate dose →

Side Effects

  • Generally well tolerated in research studies
  • Mild local reactions at injection site (if injected)
  • No significant systemic side effects reported at standard doses

Contraindications

Not FDA approved. Limited long-term safety data. Use with caution in active respiratory infections or known hypersensitivity to peptide components.

Storage

Store at 2–8°C. Protect from moisture and light.

  1. 1.
    Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum

    Fedoreyeva LI, Dilovarova TA, Ashapkin VV, Martirosyan YT, Khavinson VK, Kharchenko PN et al. · Biochemistry. Biokhimiia · 2017PubMed Verified

  2. 2.
    Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology

    Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON · Bulletin of experimental biology and medicine · 2015PubMed Verified

  3. 3.
    Peptides tissue-specifically stimulate cell differentiation during their aging

    Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM · Bulletin of experimental biology and medicine · 2012PubMed Verified

  4. 4.
  5. 5.
    Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability

    Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA et al. · Bulletin of experimental biology and medicine · 2011PubMed Verified

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice. Many compounds listed are research chemicals not approved for human use. Always consult a qualified healthcare professional before starting any protocol.

Was this page helpful?

Launching soon

Build and track your protocol in Staqk

Log doses, track timing, monitor biomarkers, and manage every compound in your stack — all in one place.

Free early access updates. No spam.